These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25029780)

  • 1. Managed care considerations. Optimal pharmacotherapy of schizophrenia.
    Muller R
    Manag Care; 2014 Apr; 23(4 Suppl 1):4. PubMed ID: 25029780
    [No Abstract]   [Full Text] [Related]  

  • 2. Delaying time to relapse in schizophrenia. The role of long-acting injectable antipsychotics.
    Muller R
    Manag Care; 2014 Apr; 23(4 Suppl 1):2-3. PubMed ID: 25029779
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.
    Zeidler J; Mahlich J; Greiner W; Heres S
    Appl Health Econ Health Policy; 2013 Oct; 11(5):509-21. PubMed ID: 23975630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention.
    Agid O; Foussias G; Remington G
    Expert Opin Pharmacother; 2010 Oct; 11(14):2301-17. PubMed ID: 20586707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Financial impact of a pharmacist-managed clinic for long-acting injectable antipsychotics.
    Phan SV; VandenBerg AM
    Am J Health Syst Pharm; 2012 Jun; 69(12):1014-5. PubMed ID: 22644972
    [No Abstract]   [Full Text] [Related]  

  • 6. New advances in pharmacotherapy for early psychosis.
    Emsley R
    Early Interv Psychiatry; 2009 Sep; 3 Suppl 1():S8-12. PubMed ID: 21352195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.
    Rosenheck RA; Krystal JH; Lew R; Barnett PG; Thwin SS; Fiore L; Valley D; Huang GD; Neal C; Vertrees JE; Liang MH;
    Clin Trials; 2011 Apr; 8(2):196-204. PubMed ID: 21270143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia.
    Hong J; Novick D; Brugnoli R; Bertsch J; Haro JM
    Hum Psychopharmacol; 2013 Sep; 28(5):438-46. PubMed ID: 23775950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left behind: the seriously mentally ill in the managed care era. Interview by Robin Dorman.
    Torrey EF; Fisher D
    Behav Healthc Tomorrow; 1998 Dec; 7(6):12-4, 31-3. PubMed ID: 10187561
    [No Abstract]   [Full Text] [Related]  

  • 10. The cost of schizophrenia.
    Wasylenki DA
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S65-9. PubMed ID: 7874667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost analysis of the strategies in the treatment of schizophrenics: the place of sustained release injectable atypical antipsychotics].
    Gasquet I; Bouhassira M; Launois R
    Encephale; 2005; 31(4 Pt 1):517-8. PubMed ID: 16389719
    [No Abstract]   [Full Text] [Related]  

  • 12. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
    Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
    J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical antipsychotics in the managed care era.
    Loebel AD; Botts SR; Feldman BI
    Am J Manag Care; 1998 Jan; 4 Suppl():S37-50; quiz S51-2. PubMed ID: 10181074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration.
    Ren XS; Crivera C; Sikirica M; Dirani R; Qian S; Kazis LE
    J Clin Pharm Ther; 2011 Jun; 36(3):383-9. PubMed ID: 21062329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacoeconomic review of the use of injectable long-acting risperidone].
    Bartkó G; Fehér L
    Neuropsychopharmacol Hung; 2005 Dec; 7(4):199-207. PubMed ID: 16496485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.
    Keith S
    Expert Rev Neurother; 2009 Jan; 9(1):9-31. PubMed ID: 19102665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Access to atypical antipsychotics: a public payor's perspective.
    Haveman JK
    Behav Healthc Tomorrow; 1998 Aug; 7(4):45-8. PubMed ID: 10182153
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.
    Offord S; Lin J; Mirski D; Wong B
    Adv Ther; 2013 Mar; 30(3):286-97. PubMed ID: 23483449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Annual health outcomes and treatment costs for schizophrenia populations.
    Mauskopf JA; David K; Grainger DL; Gibson PJ
    J Clin Psychiatry; 1999; 60 Suppl 19():14-9; discussion 20-2. PubMed ID: 10507276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence and outcomes associated with copayment burden in schizophrenia: a cross-sectional survey.
    Kim E; Gupta S; Bolge S; Chen CC; Whitehead R; Bates JA
    J Med Econ; 2010; 13(2):185-92. PubMed ID: 20235753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.